These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35993952)

  • 21. Wnt pathway-related three-mRNA clinical outcome signature in bladder urothelial carcinoma: computational biology and experimental analyses.
    Sun S; Wang Y; Wang J; Bi J
    J Transl Med; 2021 Sep; 19(1):409. PubMed ID: 34579753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
    Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
    Front Immunol; 2022; 13():916800. PubMed ID: 35860239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Hub Genes Associated with Progression and Prognosis of Bladder Cancer by Integrated Bioinformatics Analysis.
    Jiang S; Ma J; Wei S; Ren P; Liu J; Zhou Y; Liu D; Zhang X
    Arch Esp Urol; 2022 Nov; 75(9):779-790. PubMed ID: 36472061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrated transcriptome analysis of CSE1L regarding poor prognosis and immune infiltration in bladder urothelial carcinoma and experimental verification.
    Liu R; Ma J; Zhang Y; Zhou Z
    Front Immunol; 2024; 15():1449251. PubMed ID: 39430746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Multiomics Profiling Based on Online Database Revealed Prognostic Biomarkers of BLCA.
    Li H; Chen S; Mi H
    Biomed Res Int; 2022; 2022():2449449. PubMed ID: 35669725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
    BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
    Qiu Y; Ye W; Wang C; Zang J
    Aging (Albany NY); 2023 Nov; 15(22):13312-13328. PubMed ID: 38015710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.
    Sun Z; Jing C; Zhan H; Guo X; Suo N; Kong F; Tao W; Xiao C; Hu D; Wang H; Jiang S
    Front Immunol; 2023; 14():1097472. PubMed ID: 36761744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes.
    Zhao H; Chen Z; Fang Y; Su M; Xu Y; Wang Z; Gyamfi MA; Zhao J
    J Immunol Res; 2022; 2022():1793005. PubMed ID: 35450397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive Analysis of the Expression, Prognosis, and Biological Significance of PLOD Family in Bladder Cancer.
    Chen R; Jiang M; Hu B; Fu B; Sun T
    Int J Gen Med; 2023; 16():707-722. PubMed ID: 36872941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    Li Y; Xu K; Zhang Y; Mao H; Qiu Q; Yan Z; Liu X; Du Y; Chen Z
    BMC Cancer; 2023 Oct; 23(1):1021. PubMed ID: 37872487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
    Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
    Front Genet; 2021; 12():696912. PubMed ID: 34512722
    [No Abstract]   [Full Text] [Related]  

  • 37. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
    Shi X; Dong A; Yang Y; Zheng G; Wang N; Yang C; Wang Y; Lu J; Jia X
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):9733-9746. PubMed ID: 37244876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism-related genes and their relationships with immune infiltration.
    Huang C; Li Y; Ling Q; Wei C; Fang B; Mao X; Yang R; Zhang L; Huang S; Cheng J; Liao N; Wang F; Mo L; Mo Z; Li L
    FEBS Open Bio; 2023 Apr; 13(4):736-750. PubMed ID: 36814419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGL2 as a predictive biomarker for prognosis and immunotherapy in bladder cancer.
    Huang Z; Wang Z; Xu C; Yan Y; Cao X; Zhang F; Shen B
    Int J Med Sci; 2024; 21(8):1447-1460. PubMed ID: 38903931
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and
    Dong Y; Xu C; Su G; Li Y; Yan B; Liu Y; Yin T; Mou S; Mei H
    Front Immunol; 2023; 14():1122570. PubMed ID: 37275895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.